Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, announced that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has entered into a tolling agreement. The agreement outlines the extraction of 80–85% pure CBD distillate from an initial 500 kgs of hemp biomass, sourced from one of Pure Extracts’ preferred suppliers. The distillate has a CBD potency of over 10%. The announcement noted that the biomass has a specific particulate mill size and runs efficiently on PULL’s Vitalis R200 sub/super-critical CO2extraction system. The company also observed that extracted CBD distillate is an ideal ingredient for vape cartridges, topicals, beverages and edible gummies and chocolates because of its high level of purity. “We are pleased to have entered into this tolling agreement and to have taken delivery of the first 500 kg of milled hemp biomass,” said Pure Extracts CEO Ben Nikolaevsky. “We are very familiar with this particular biomass having used it before in the manufacturing of our in-house, branded products, so we know it extracts very well.”
To view the full press release, visit https://ibn.fm/SeBxJ
About Pure Extracts Technologies Corp.
Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On Sept. 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act. In addition, the company’s stock began trading on the Canadian Securities Exchange (“CSE”) on Nov. 5, 2020. For more information about the company, please visit www.PureExtractsCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
The Psychedelic Therapeutics and Drug Development announced that PsychedelicNewsWire (“PNW), a specialized communications platform for…
Arrowhead Sci-Tech Conferences and Events today announced the 4th Annual Psychedelic Therapeutics and Drug Development…
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a…
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative…
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) today provided an update by way of a…
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) today provided an update by way of a…